Home

Metsera, Inc. - Common Stock (MTSR)

63.73
+11.52 (22.06%)
NASDAQ · Last Trade: Oct 31st, 3:15 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close52.21
Open62.81
Bid63.00
Ask64.25
Day's Range62.65 - 66.10
52 Week Range12.30 - 66.10
Volume9,514,804
Market Cap-
PE Ratio (TTM)-4.952
EPS (TTM)-12.9
Dividend & YieldN/A (N/A)
1 Month Average Volume1,702,762

Chart

News & Press Releases

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promisestocktwits.com
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.
Via Stocktwits · October 31, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · October 30, 2025
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metserainvestors.com
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.
Via Investor's Business Daily · October 30, 2025
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · October 30, 2025
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metserastocktwits.com
Via Stocktwits · October 30, 2025
Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizerstocktwits.com
Via Stocktwits · October 30, 2025
Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalystsstocktwits.com
Via Stocktwits · October 6, 2025
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'benzinga.com
Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action.
Via Benzinga · October 30, 2025
The market is filled with gapping stocks in Thursday's session.chartmill.com
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · October 30, 2025
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursdaybenzinga.com
Via Benzinga · October 30, 2025
Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · October 30, 2025
2 High-Yield Stocks With Fresh Catalystsfool.com
Income investors can capture yields above 5% from companies executing business transformations.
Via The Motley Fool · October 29, 2025
Google Parent Alphabet Has $754 Million Invested in These 3 Hot Growth Stocks. Here's the 1 Wall Street Likes the Most.fool.com
At least one of these stocks owned by Alphabet could be a great pick for aggressive investors.
Via The Motley Fool · October 27, 2025
2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Foreverfool.com
Both companies are monsters in their industry and are poised to thrive.
Via The Motley Fool · October 25, 2025
HALPER SADEH LLC ENCOURAGES MTSR, HOLX, MRUS SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 
By Halper Sadeh LLC · Via GlobeNewswire · October 23, 2025
Metsera Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Metsera, Inc. (NasdaqGS: MTSR) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Metsera will receive $47.50 per share in cash at closing, plus a non-transferable contingent value right entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
By Kahn Swick & Foti, LLC · Via Business Wire · October 23, 2025
2 Mega-Dividend Stocks With Yields As High As 7%fool.com
Dividend stocks with high yields can be great investment opportunities, but those yields can also be red flags.
Via The Motley Fool · October 21, 2025
Down 44%, Should You Buy the Dip on Viking Therapeutics?fool.com
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.
Via The Motley Fool · October 13, 2025
Where Will Pfizer Be in 5 Years?fool.com
Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past.
Via The Motley Fool · October 13, 2025
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, MTSR, HOUS, ODP on Behalf of Shareholders
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · October 7, 2025
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
BALA CYNWYD, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · October 7, 2025
Down 50%, Should You Buy the Dip on Pfizer?fool.com
Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.
Via The Motley Fool · October 7, 2025
3 Reasons to Buy Pfizer Stock Nowfool.com
After years of underperformance, the future is looking brighter for the drugmaker.
Via The Motley Fool · October 6, 2025
2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 in Octoberfool.com
You don't need to be rich to put your money to work on Wall Street.
Via The Motley Fool · October 3, 2025
3 Things You Need to Know if You Buy Pfizer Todayfool.com
Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it.
Via The Motley Fool · October 2, 2025